Access IBEC scientific production portal (IBEC CRIS), for more detailed information and advanced search features.
Find here the list of all IBEC's publications by year.
by Keyword: Cell-lines
Almeida, Joana, Resende, Diana I S P, Silva, Rita, Villasante, Aranzazu, Murphy, Catherine, Zingales, Veronica, Palmeira, Andreia, Skoda, Jan, Broso, Francesca, Vadivellu, Aiswariya, Oliveira, Paula, Reis, Salette, Nunes, Claudia, Loh, Amos Hong Pheng, Ferreira, Joana M, Martins, Eduarda P, Costa, Bruno M, Inga, Alberto, Samitier, Josep, Sousa, Emilia, Saraiva, Lucilia, (2025). Improving neuroblastoma therapy with a new p53 family-activating agent European Journal Of Pharmacology 1007, 178295 
Neuroblastoma (NB) is among the most common malignancies in children and represents a therapeutic challenge in pediatric oncology. p53 family proteins play a critical role in protecting cells from genomic instability and malignant transformation. However, in NB, their activities are often inhibited by interacting proteins such as MDM2. The interplay between p53 family pathway and N-Myc, a key biomarker of poor prognosis, is also a critical factor in NB pathogenesis. Herein, we disclose 1-(dibromomethyl)-3,4,6-trimethoxy-9H-xanthen-9-one (LEM3) as a new p53 family-activating agent with potent NB anticancer activity. At 0.13-2.1 mu M, LEM3 inhibited the growth of several NB cell lines. Its activity was further evidenced in spheroids, patient-derived NB cells, and in a vasculature stiffness-based model of MYCN-amplified NB cells. This growth-inhibitory effect was associated with cell cycle arrest and apoptosis, in SH-SY5Y and SK-N-BE(2) NB cells, without apparent acquisition of resistance. LEM3 inhibited cell migration and invasion and reduced the expression of NB-related prognostic markers, particularly MYCN mRNA and protein levels. LEM3 released p53, TAp63, and TAp73 from their interaction with MDM2 both in a yeast-based assay and NB cells; for p53, this led to increased protein stabilization, DNA-binding ability, and transcriptional activity. Fluorescence quenching and docking analyses suggested that LEM3 binds to p53, TAp63, and TAp73 at the MDM2-binding site within their transactivation domain. LEM3 also synergies with doxorubicin and cisplatin in NB cells. Given the central role of the p53 family MDM2-MYCN axis in NB pathogenesis, our findings support LEM3 as a promising compound for advancing NB targeted therapy.
JTD Keywords: Amplification, Cell-lines, Expression, High-risk neuroblastoma, Mdm2, Mutant p53, N-myc, N-myc oncogene, Neuroblastoma, P53 family proteins, P53/mdm2/p14(arf) pathway, P73, Sensitizes neuroblastoma, Targeted anticancer therapy, Xanthone derivative
Llorens, Franc, Hummel, Manuela, Pastor, Xavier, Ferrer, Anna, Pluvinet, Raquel, Vivancos, Ana, Castillo, Ester, Iraola, Susana, Mosquera, Ana M., Gonzalez, Eva, Lozano, Juanjo, Ingham, Matthew, Dohm, Juliane C., Noguera, Marc, Kofler, Robert, Antonio del Rio, Jose, Bayes, Monica, Himmelbauer, Heinz, Sumoy, Lauro, (2011). Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis BMC Genomics 12, 326
Background: Epidermal Growth Factor (EGF) is a key regulatory growth factor activating many processes relevant to normal development and disease, affecting cell proliferation and survival. Here we use a combined approach to study the EGF dependent transcriptome of HeLa cells by using multiple long oligonucleotide based microarray platforms (from Agilent, Operon, and Illumina) in combination with digital gene expression profiling (DGE) with the Illumina Genome Analyzer.
Results: By applying a procedure for cross-platform data meta-analysis based on RankProd and GlobalAncova tests, we establish a well validated gene set with transcript levels altered after EGF treatment. We use this robust gene list to build higher order networks of gene interaction by interconnecting associated networks, supporting and extending the important role of the EGF signaling pathway in cancer. In addition, we find an entirely new set of genes previously unrelated to the currently accepted EGF associated cellular functions.
Conclusions: We propose that the use of global genomic cross-validation derived from high content technologies (microarrays or deep sequencing) can be used to generate more reliable datasets. This approach should help to improve the confidence of downstream in silico functional inference analyses based on high content data.
JTD Keywords: Gene-expression measurements, Quality-control maqc, Cancer-cell-lines, Real-time pcr, Oligonucleotide microarrays, Phosphorylation dynamics, In-vivo, Networks, Signal, Technologies
